Source: ERS Lung Science Conference 2020
Disease area: -



Rating:

Share or cite this content

Citations should be made in the following way:
Yan Hui Giam (Dundee, United Kingdom). Validation of AMP-activated protein kinase as a therapeutic target in bronchiectasis. ERS Lung Science Conference 2020

Member's Comments

No comment yet.

Related content which might interest you: Increased phosphorylated p38 mitogen-activated protein kinase in COPD lungs Source: Eur Respir J 2013; 42: 28-41 Year: 2013 Role of p38 mitogen-activated protein kinase in trauma/hemorrhage and subsequent peumococcal pneumonia Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations Year: 2010 The effects of oral p38 mitogen activated protein kinase (MAPK) inhibitor SB-681323 on blood biomarkers in COPD Source: Annual Congress 2008 - Novel treatments for respiratory disease Year: 2008 Inhibition of p38 MAPK-dependent bronchial contraction after ozone by corticosteroids Source: Eur Respir J 2011; 37: 933-942 Year: 2011 Ventilation-induced activation of the mitogen-activated protein kinase pathway Source: Eur Respir J 2002; 20: 946-956 Year: 2002 Pulmonary complications of Bcr-Abl tyrosine kinase inhibitors Source: Eur Respir J, 56 (4) 2000279; 10.1183/13993003.00279-2020 Year: 2020 Effect of fudosteine on mucin production Source: Eur Respir J 2008; 32: 1195-1202 Year: 2008 LATE-BREAKING ABSTRACT: Evaluation of an oral p38 mitogen activated protein kinase (MAPK inhibitor) SB-681323 in COPD Source: Annual Congress 2009 - COPD: from biomarker profiling to clinical assessment Year: 2009 Inhibition of phosphatidylinositol 3-kinase and mitogen-activated protein kinase kinase prevents malignant pleural mesothelioma cell growth Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 c-Jun N-terminal kinase-dependent mechanisms in respiratory disease Source: Eur Respir J 2006; 28: 651-661 Year: 2006 Inhibition of p38 mitogen-activated protein kinase has no effect on macrophage phagocytosis of bacteria in patients with COPD Source: Annual Congress 2013 –Macrophages, mononuclear cells and viral infection Year: 2013 Transmission of muscarinic receptor mediated proliferative effects in human lung fibroblasts involves ERK-MAP kinase, but not PI-3 kinase and Rho-kinase pathway Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007 Experience of using Janus kinase inhibitors in COVID-19 Source: Virtual Congress 2021 – Highlights in COVID-19 diagnosis and treatment Year: 2021 Mitogen activated protein kinase activated protein kinase 2 regulates actin stress fiber formation in ventilator associated lung injury Source: Annual Congress 2008 - Pulmonary vascular biology Year: 2008 Inhibition of Pim1 kinase, new therapeutic approach in virus-induced asthma exacerbations Source: Eur Respir J 2016; 47: 783-791 Year: 2016 Expression of the phosphorylated myristoylated alanine-rich C kinase substrate (MARCKS) in COPD bronchial glands Source: Annual Congress 2011 - COPD: human studies Year: 2011 Mice deficient in Raf kinase inhibitor protein (RKIP) have elevated indices of pulmonary hypertension Source: Annual Congress 2010 - Experimental pulmonary hypertension Year: 2010